TAILIEUCHUNG - Chapter 104. Acute and Chronic Myeloid Leukemia (Part 6)

Most patients are anemic and thrombocytopenic at presentation. Replacement of the appropriate blood components, if necessary, should begin promptly. Because qualitative platelet dysfunction or the presence of an infection may increase the likelihood of bleeding, evidence of hemorrhage justifies the immediate use of platelet transfusion, even if the platelet count is only moderately decreased. About 50% of patients have a mild to moderate elevation of serum uric acid at presentation. Only 10% have marked elevations, but renal precipitation of uric acid and the nephropathy that may result is a serious but uncommon complication. The initiation of chemotherapy may aggravate hyperuricemia,. | Chapter 104. Acute and Chronic Myeloid Leukemia Part 6 Most patients are anemic and thrombocytopenic at presentation. Replacement of the appropriate blood components if necessary should begin promptly. Because qualitative platelet dysfunction or the presence of an infection may increase the likelihood of bleeding evidence of hemorrhage justifies the immediate use of platelet transfusion even if the platelet count is only moderately decreased. About 50 of patients have a mild to moderate elevation of serum uric acid at presentation. Only 10 have marked elevations but renal precipitation of uric acid and the nephropathy that may result is a serious but uncommon complication. The initiation of chemotherapy may aggravate hyperuricemia and patients are usually started immediately on allopurinol and hydration at diagnosis. Rasburicase recombinant uric oxidase is also useful for treating uric acid nephropathy and often can normalize the serum uric acid level within hours with a single dose of treatment. The presence of high concentrations of lysozyme a marker for monocytic differentiation may be etiologic in renal tubular dysfunction which could worsen other renal problems that arise during the initial phases of therapy. Prognostic Factors Many factors influence the likelihood of entering CR the length of CR and the curability of AML. CR is defined after examination of both blood and bone marrow. The blood neutrophil count must be 1000 pL and the platelet count 100 000 pL. Hemoglobin concentration is not considered in determining CR. Circulating blasts should be absent. While rare blasts may be detected in the blood during marrow regeneration they should disappear on successive studies. Bone marrow cellularity should be 20 with trilineage maturation. The bone marrow should contain 5 blasts and Auer rods should be absent. Extramedullary leukemia should not be present. For patients in morphologic CR reverse transcriptase polymerase chain reaction RT-PCR to detect .

• Y học thường thức
• Acute and Chronic Myeloid Leukemia
• bệnh học và điều trị
• bài giảng bệnh học
• tài liệu học ngành y
• Harrisons Internal Medicine
• Chronic myeloid leukemia
• Acute myeloid leukemia
• Imatinib mesylate
• Leukemia markers
• Anti leukemia drugs in myeloid leukemia
• BMC Cancer
• Acute lymphoblastic leukemia
• Chronic lymphocytic leukemia
• Case rep
• Chemotherapeutic agents
• Phase I
• Myelodysplastic syndrome
• Chronic myelomonocytic leukemia
• Acute lympho leukemia
• Hyperleukocytic symptoms
• Clinical symptoms of leukostatsis
• Pathology competencies
• Organ system pathology
• Myeloid neoplasia
• Myelodysplastic syndromes
• Myeloproliferative neoplasms
• Tobacco smoking
• Including chronic myeloid leukemia
• Tyrosine kinase inhibitor
• Hematopoietic stem cell transplantation
• Kinase inhibitors
• báo cáo khoa học
• báo cáo y học
• công trình nghiên cứu về y học
• tài liệu về y học
• cách trình bày báo cáo